Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) is a Healthcare company (Biotechnology) with a market capitalization of $2.1B. The Maz Rating grades it against the other companies in its sector.
Maravai LifeSciences Holdings, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $7.28, Maravai LifeSciences Holdings, Inc. trades at 9.7x sales and 5.5x book value. Over the last twelve months it generated about $213M of revenue and a net loss of $127M. It runs a gross margin of 38.9%, an operating margin of -18.8% and a net margin of -30.8%. It shows return on equity of -31.9%, return on invested capital of -7.0% and a free cash flow yield of -0.6%. On the balance sheet: a debt-to-equity ratio of 1.15 and a current ratio of 4.66. Over the past 52 weeks the share price ranged from $2.80 to $9.42, with a beta of 0.63.
Maravai LifeSciences Holdings, Inc. does not currently pay a dividend.
14 Wall Street analyst ratings cover the stock: 8 Buy, 5 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Maravai LifeSciences Holdings, Inc. is a life sciences company operating globally, supplying essential products that facilitate the advancement of drug therapies, diagnostics, innovative vaccines, and research into human diseases. Its diverse product line supports critical stages of biopharmaceutical development, featuring nucleic acids for both diagnostic and therapeutic applications, antibody-based solutions for detecting impurities in biopharmaceutical manufacturing, and tools for monitoring protein expression across different tissue types. The company conducts its operations through two distinct segments: Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment specializes in manufacturing and distributing products integral to gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics. This encompasses reagents utilized in the chemical synthesis, modification, labeling, and purification of DNA and RNA. Additionally, this division provides messenger RNA, oligonucleotides, their foundational building blocks, plasmid DNA, and the proprietary CleanCap capping technology. Meanwhile, the Biologics Safety Testing segment offers analytical products vital for developing biologic manufacturing processes. Its offerings include bespoke antibody and assay development services tailored to specific products, alongside HCP ELISA kits, various other ELISA kits for identifying bioprocess impurities and contaminants, ancillary reagents, and custom service solutions. Maravai's clientele spans biopharmaceutical companies, other life sciences and biopharmaceutical research firms, academic research institutions, and in vitro diagnostics companies. Incorporated in 2020, Maravai LifeSciences Holdings, Inc. maintains its headquarters in San Diego, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
Yes. As of September 2026, Maravai LifeSciences Holdings, Inc. (MRVI) is classified as HALAL by Maz Vantage: it passes all 5 published Shariah screening standards it was tested against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 7.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 3.47% / 30% · Interest income / Revenue 1.30% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 7.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 3.47% / 33% · Receivables / Mkt Cap (36m) 1.22% / 49% · Interest income / Revenue 1.30% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 7.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 3.47% / 33.33% · Receivables / Mkt Cap (24m) 1.22% / 33.33% · Interest income / Revenue 1.30% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 21.2% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 19.6% / 33.33% · Receivables / Avg Assets (4Q) 4.31% / 33.33% · Interest income / Revenue 1.30% / 5% | Pass |
| FTSE | Debt / Total Assets 24.5% / 33.33% · (Cash+ST Inv) / Total Assets 12.2% / 33.33% · (Cash+Recv) / Total Assets 16.5% / 33.33% · Interest income / Revenue 1.30% / 5% | Pass |
Yes. As of September 2026, Maravai LifeSciences Holdings, Inc. (MRVI) is classified as HALAL by Maz Vantage: it passes all 5 published Shariah screening standards it was tested against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
Yes. Maravai LifeSciences Holdings, Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 1.30% of each dividend: Maravai LifeSciences Holdings, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.